<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00132730</url>
  </required_header>
  <id_info>
    <org_study_id>0873-005</org_study_id>
    <secondary_id>2005_015</secondary_id>
    <nct_id>NCT00132730</nct_id>
  </id_info>
  <brief_title>An Investigational Drug Study In Patients With COPD (Chronic Obstructive Pulmonary Disease) (MK-0873-005)</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study of MK-0873 in Patients With COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the effectiveness and tolerability of a once-daily oral
      medication (MK-0873) for the treatment of COPD (chronic obstructive pulmonary disease) to
      determine whether the study drug leads to an improvement in pulmonary (lung) function, as
      well as symptoms, and quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following a three-week run-in period (Period I) during which participants received placebo,
      participants entered into a 12-week double-blind treatment period (Period II) during which
      they received daily doses of either one of three doses of MK-0873 or placebo. Period I and
      Period II made up the Base Study. Following the 12-week treatment period in the Base Study,
      participants were invited to continue in an optional 12-week double-blind extension study
      (Period III, EXT1). Participants who received any dose of MK-0873 in the Base Study continued
      on MK-0873 2.5 mg daily in Period III while participants in the placebo arm of the Base Study
      continued on placebo daily. Following EXT1, participants were invited to continue in an
      optional open-label second extension study (EXT2) which was to last 80 weeks (Period IV: 28
      weeks, Period V: 52 weeks). In EXT2, participants who had been taking MK-0873 2.5 mg in the
      Base Study were allocated to MK-0873 2.5 mg plus usual care, while participants who had been
      taking the other two doses of MK-0873 or placebo in the Base Study were allocated to either
      MK-0873 2.5 mg plus usual care or to usual care alone.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">June 1, 2004</start_date>
  <completion_date type="Actual">August 17, 2005</completion_date>
  <primary_completion_date type="Actual">August 17, 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Pre-dose (Trough) Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Pre-dose at Baseline and Treatment Weeks 8, 10 and 12</time_frame>
    <description>FEV1 is a measure, in liters, of the amount of air expired in 1 second. Measured values were averaged during the placebo run-in period for baseline and over the last 4 weeks of the 12-week treatment period for on-treatment. For participants who did not have any measurements over the last 4 weeks of the 12-week treatment period, the last available on-treatment measurement was carried forward.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Overall Daytime Symptoms Score</measure>
    <time_frame>Baseline and Treatment Weeks 8, 10 and 12</time_frame>
    <description>On a daily diary card, participants rated their responses to the question &quot;Overall, how much of the time did you have symptoms from your lung disease today?&quot; (0=none of the time; 5=all of the time). Scores range from 0 to 5, with higher scores indicating more time with symptoms. The overall daytime symptoms score value was the mean daily diary score during the placebo run-in period for baseline and over the last 4 weeks of the 12-week treatment period for on-treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Daily Beta-agonist Use</measure>
    <time_frame>Baseline and Treatment Weeks 8, 10 and 12</time_frame>
    <description>The total daily beta-agonist use was measured in puffs per day and was recorded on daily diary cards by participants. It is defined as the sum of beta-agonist use between when participants arose from and went to bed. The total daily beta-agonist use values were the recorded mean during the placebo run-in period for baseline and over the last 4 weeks of the 12-week treatment period for on-treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Response</measure>
    <time_frame>Baseline and Treatment Weeks 8 and 12</time_frame>
    <description>The SGRQ consists of 76 items in 3 domains: Symptoms (frequency and severity), Activity (activities that cause or are limited by breathlessness) and Impacts (social functioning, psychological disturbances resulting from airways disease). Scores for each domain and a total score are calculated; each questionnaire response has a unique empirically dervied &quot;weight&quot;. Scores range from 0 to 100, with higher scores indicating poor health. Each domain of the questionnaire is scored separately in 2 steps: 1) The weights for all items with a positive response are summed; 2) The score is calculated by dividing the summed weights by the maximum possible weight for that domain and expressing the results as a percentage. The mean SGRQ scores were calculated during the placebo run-in period for baseline and over the last 4 weeks of the 12-week treatment period for on-treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transition Dyspnea Index (TDI) Focal Score</measure>
    <time_frame>Baseline and Treatment Week 12</time_frame>
    <description>The baseline dyspnea index (BDI) was measured at the randomization visit as a 3-domain score with a scale of 0 to 4 in each domain, with a total focal score of 12 indicating no dyspnea limitation and 0 indicating severe dyspnea. After 12 weeks of treatment, the investigator-administered TDI was completed, with a change in each of the 3 domains being rated from -3 (major deterioration) to +3 (major improvement), so that the TDI focal score could range from -9 to +9. A higher TDI focal score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Shortness of Breath Questionnaire (SOBQ) Response</measure>
    <time_frame>Baseline and Treatment Weeks 8 and 12</time_frame>
    <description>The SOBQ is a validated 24-item measure of dyspnea associated with activities of daily living in patients with moderate to severe chronic lung disease. Twenty-one items ask patients about how frequently they experience shortness of breath (SOB) on a 6-point scale of 0 (never) to 5 (activity given up due to dyspnea) when performing various tasks. Three additional questions about limitations due to SOB, fear of harm from overexertion and fear of SOB are included for a total of 24 items. If patients do not routinely perform the activity indicated in the questionnaire, they are asked to estimate the degree of SOB anticipated. The SOBQ total score is calculated by summing responses across all 24 items. The total score ranges from 0 to 120, with a higher score indicating greater frequency of and limitations due to SOB. The score assessed at the baseline visit was used for the baseline score and the mean score assessed at Treatment Weeks 8 and 12 was used as the on-treatment score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With at Least One Chronic Obstructive Pulmonary Disease (COPD) Exacerbation</measure>
    <time_frame>Baseline through Treatment Week 12</time_frame>
    <description>COPD exacerbation is defined as any change in symptoms or functional status that leads to administration (at investigator's discretion) of systemic corticosteroids (above participant's usual dose) and/or antibiotics, or an unscheduled COPD-related hospitalization, emergency room visit, or doctor visit. The number of participants who experienced at least one COPD exacerbation during the 12-week treatment period is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Predose (Trough) Forced Vital Capacity (FVC)</measure>
    <time_frame>Predose at Baseline and Treatment Weeks 8, 10 and 12</time_frame>
    <description>FVC is a measure, in liters and using a spirometer, of the amount of air forcibly exhaled from the lungs after taking the deepest breath possible. The values averaged during the placebo run-in period were used for the baseline measurement and the values averaged over Treatment Weeks 8, 10 and 12 were used for the on-treatment measurement. A higher value indicates greater lung exiratory function.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">604</enrollment>
  <condition>Lung Diseases</condition>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>MK-0873 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 2.5 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-0873 1.25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 1.25 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-0873 0.75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 0.75 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), placebo tablets once daily for 12 weeks in Period II (Base) and placebo tablets once daily for 12 weeks in Period III (EXT1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-0873 2.5 mg + Usual Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive MK-0873 2.5 mg tablets once daily plus usual care (inhaled short- or long-acting beta-agonists, inhaled corticosteroids, or short- or long-acting anticholinergics) for 28 weeks during Periods IV and V (EXT2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive usual care (inhaled short- or long-acting beta-agonists, inhaled corticosteroids, or short- or long-acting anticholinergics) for 28 weeks during Periods IV and V (EXT2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-0873 2.5 mg</intervention_name>
    <arm_group_label>MK-0873 2.5 mg</arm_group_label>
    <arm_group_label>MK-0873 2.5 mg + Usual Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-0873 1.25 mg</intervention_name>
    <arm_group_label>MK-0873 1.25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-0873 0.75 mg</intervention_name>
    <arm_group_label>MK-0873 0.75 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to MK-0873</intervention_name>
    <arm_group_label>MK-0873 2.5 mg</arm_group_label>
    <arm_group_label>MK-0873 1.25 mg</arm_group_label>
    <arm_group_label>MK-0873 0.75 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <arm_group_label>MK-0873 2.5 mg + Usual Care</arm_group_label>
    <arm_group_label>Usual Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females, 40 to 75 years old, with a history consistent with COPD (chronic
             obstructive pulmonary disease)

          -  Lung function tests that meet the requirements of the study

        Exclusion Criteria:

          -  Severe and unstable medical conditions other than COPD (chronic obstructive pulmonary
             disease)

          -  Use of continuous oxygen therapy

          -  Cardiac (heart) arrhythmias

          -  Other lung disease

          -  History of colitis (inflammation of the colon)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2005</study_first_submitted>
  <study_first_submitted_qc>August 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2005</study_first_posted>
  <results_first_submitted>March 17, 2014</results_first_submitted>
  <results_first_submitted_qc>April 25, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 26, 2014</results_first_posted>
  <last_update_submitted>March 24, 2017</last_update_submitted>
  <last_update_submitted_qc>March 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>MK 0873</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=0873-005&amp;kw=0873-005&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MK-0873 0.75 mg Base Study</title>
          <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), and MK-0873 0.75 mg tablets once daily for 12 weeks in Period II (Base)</description>
        </group>
        <group group_id="P2">
          <title>MK-0873 1.25 mg Base Study</title>
          <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), and MK-0873 1.25 mg tablets once daily for 12 weeks in Period II (Base)</description>
        </group>
        <group group_id="P3">
          <title>MK-0873 2.5 mg Base Study</title>
          <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 2.5 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)</description>
        </group>
        <group group_id="P4">
          <title>Placebo Base Study</title>
          <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), placebo tablets once daily for 12 weeks in Period II (Base) and placebo tablets once daily for 12 weeks in Period III (EXT1)</description>
        </group>
        <group group_id="P5">
          <title>MK-0873 2.5 mg + Usual Care</title>
          <description>Participants receive MK-0873 2.5 mg tablets once daily plus usual care (inhaled short- or long-acting beta-agonists, inhaled corticosteroids, or short- or long-acting anticholinergics) for 28 weeks in Periods IV and V (EXT2)</description>
        </group>
        <group group_id="P6">
          <title>Usual Care</title>
          <description>Participants receive usual care (inhaled short- or long-acting beta-agonists, inhaled corticosteroids, or short- or long-acting anticholinergics) for 28 weeks in Periods IV and V (EXT2)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period I - Placebo Run-in (Base)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="150"/>
                <participants group_id="P2" count="148"/>
                <participants group_id="P3" count="153"/>
                <participants group_id="P4" count="153"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="150"/>
                <participants group_id="P2" count="148"/>
                <participants group_id="P3" count="153"/>
                <participants group_id="P4" count="153"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period II - 12-week Treatment (Base)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="150"/>
                <participants group_id="P2" count="148"/>
                <participants group_id="P3" count="153"/>
                <participants group_id="P4" count="153"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
                <participants group_id="P2" count="133"/>
                <participants group_id="P3" count="135"/>
                <participants group_id="P4" count="131"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Clinical adverse experience</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Laboratory adverse experience</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period III - Blinded Extension (EXT1)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="317">Includes all MK-0873 participants from Period II. Not all eligible participants entered EXT1</participants>
                <participants group_id="P4" count="107">Not all eligible participants entered EXT1</participants>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="235"/>
                <participants group_id="P4" count="82"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="82"/>
                <participants group_id="P4" count="25"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Site terminated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="57"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinical adverse experience</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Laboratory adverse experience</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period IV - Open-label Extension (EXT2)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="187">Includes participants from Period III. Not all eligible participants entered EXT2</participants>
                <participants group_id="P6" count="71">Includes paricipants from Period III. Not all eligible participants entered EXT2</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="179"/>
                <participants group_id="P6" count="68"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Site terminated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="169"/>
                <participants group_id="P6" count="68"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinical adverse experience</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Laboratory adverse experience</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period V - Open-label Extension (EXT2)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="7">Not all participants who completed Period IV entered Period V</participants>
                <participants group_id="P6" count="2">Not all participants who completed Period IV entered Period V</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Site terminated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MK-0873 0.75 mg Base Study</title>
          <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 0.75 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)</description>
        </group>
        <group group_id="B2">
          <title>MK-0873 1.25 mg Base Study</title>
          <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 1.25 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)</description>
        </group>
        <group group_id="B3">
          <title>MK-0873 2.5 mg Base Study</title>
          <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 2.5 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)</description>
        </group>
        <group group_id="B4">
          <title>Placebo Base Study</title>
          <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), placebo tablets once daily for 12 weeks in Period II (Base) and placebo tablets once daily for 12 weeks in Period III (EXT1)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="150"/>
            <count group_id="B2" value="148"/>
            <count group_id="B3" value="153"/>
            <count group_id="B4" value="153"/>
            <count group_id="B5" value="604"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Number of Participants Between 42 and 77 Years of Age</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="148"/>
                    <measurement group_id="B3" value="153"/>
                    <measurement group_id="B4" value="153"/>
                    <measurement group_id="B5" value="604"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="167"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="108"/>
                    <measurement group_id="B4" value="112"/>
                    <measurement group_id="B5" value="437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Pre-dose (Trough) Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>FEV1 is a measure, in liters, of the amount of air expired in 1 second. Measured values were averaged during the placebo run-in period for baseline and over the last 4 weeks of the 12-week treatment period for on-treatment. For participants who did not have any measurements over the last 4 weeks of the 12-week treatment period, the last available on-treatment measurement was carried forward.</description>
        <time_frame>Pre-dose at Baseline and Treatment Weeks 8, 10 and 12</time_frame>
        <population>The modified intention-to-treat (ITT) population includes all participants who had a baseline and at least one posttreatment measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0873 0.75 mg Base Study</title>
            <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 0.75 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)</description>
          </group>
          <group group_id="O2">
            <title>MK-0873 1.25 mg Base Study</title>
            <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 1.25 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)</description>
          </group>
          <group group_id="O3">
            <title>MK-0873 2.5 mg Base Study</title>
            <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 2.5 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)</description>
          </group>
          <group group_id="O4">
            <title>Placebo Base Study</title>
            <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), placebo tablets once daily for 12 weeks in Period II (Base) and placebo tablets once daily for 12 weeks in Period III (EXT1)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pre-dose (Trough) Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>FEV1 is a measure, in liters, of the amount of air expired in 1 second. Measured values were averaged during the placebo run-in period for baseline and over the last 4 weeks of the 12-week treatment period for on-treatment. For participants who did not have any measurements over the last 4 weeks of the 12-week treatment period, the last available on-treatment measurement was carried forward.</description>
          <population>The modified intention-to-treat (ITT) population includes all participants who had a baseline and at least one posttreatment measurement.</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="153"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.005" lower_limit="-0.032" upper_limit="0.023"/>
                    <measurement group_id="O2" value="-0.037" lower_limit="-0.065" upper_limit="-0.009"/>
                    <measurement group_id="O3" value="-0.015" lower_limit="-0.043" upper_limit="0.012"/>
                    <measurement group_id="O4" value="-0.010" lower_limit="-0.038" upper_limit="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Overall Daytime Symptoms Score</title>
        <description>On a daily diary card, participants rated their responses to the question &quot;Overall, how much of the time did you have symptoms from your lung disease today?&quot; (0=none of the time; 5=all of the time). Scores range from 0 to 5, with higher scores indicating more time with symptoms. The overall daytime symptoms score value was the mean daily diary score during the placebo run-in period for baseline and over the last 4 weeks of the 12-week treatment period for on-treatment.</description>
        <time_frame>Baseline and Treatment Weeks 8, 10 and 12</time_frame>
        <population>The modified ITT population includes all participants who had a baseline and at least one posttreatment measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0873 0.75 mg Base Study</title>
            <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 0.75 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)</description>
          </group>
          <group group_id="O2">
            <title>MK-0873 1.25 mg Base Study</title>
            <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 1.25 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)</description>
          </group>
          <group group_id="O3">
            <title>MK-0873 2.5 mg Base Study</title>
            <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 2.5 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)</description>
          </group>
          <group group_id="O4">
            <title>Placebo Base Study</title>
            <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), placebo tablets once daily for 12 weeks in Period II (Base) and placebo tablets once daily for 12 weeks in Period III (EXT1)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Overall Daytime Symptoms Score</title>
          <description>On a daily diary card, participants rated their responses to the question &quot;Overall, how much of the time did you have symptoms from your lung disease today?&quot; (0=none of the time; 5=all of the time). Scores range from 0 to 5, with higher scores indicating more time with symptoms. The overall daytime symptoms score value was the mean daily diary score during the placebo run-in period for baseline and over the last 4 weeks of the 12-week treatment period for on-treatment.</description>
          <population>The modified ITT population includes all participants who had a baseline and at least one posttreatment measurement.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" lower_limit="-0.24" upper_limit="-0.06"/>
                    <measurement group_id="O2" value="-0.11" lower_limit="-0.21" upper_limit="-0.02"/>
                    <measurement group_id="O3" value="-0.13" lower_limit="-0.22" upper_limit="-0.04"/>
                    <measurement group_id="O4" value="-0.14" lower_limit="-0.23" upper_limit="-0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Daily Beta-agonist Use</title>
        <description>The total daily beta-agonist use was measured in puffs per day and was recorded on daily diary cards by participants. It is defined as the sum of beta-agonist use between when participants arose from and went to bed. The total daily beta-agonist use values were the recorded mean during the placebo run-in period for baseline and over the last 4 weeks of the 12-week treatment period for on-treatment.</description>
        <time_frame>Baseline and Treatment Weeks 8, 10 and 12</time_frame>
        <population>The modified ITT population includes all participants who had a baseline and at least one posttreatment measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0873 0.75 mg Base Study</title>
            <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 0.75 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)</description>
          </group>
          <group group_id="O2">
            <title>MK-0873 1.25 mg Base Study</title>
            <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 1.25 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)</description>
          </group>
          <group group_id="O3">
            <title>MK-0873 2.5 mg Base Study</title>
            <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 2.5 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)</description>
          </group>
          <group group_id="O4">
            <title>Placebo Base Study</title>
            <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), placebo tablets once daily for 12 weeks in Period II (Base) and placebo tablets once daily for 12 weeks in Period III (EXT1)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Daily Beta-agonist Use</title>
          <description>The total daily beta-agonist use was measured in puffs per day and was recorded on daily diary cards by participants. It is defined as the sum of beta-agonist use between when participants arose from and went to bed. The total daily beta-agonist use values were the recorded mean during the placebo run-in period for baseline and over the last 4 weeks of the 12-week treatment period for on-treatment.</description>
          <population>The modified ITT population includes all participants who had a baseline and at least one posttreatment measurement.</population>
          <units>Puffs per day of beta-agonist</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" lower_limit="-0.45" upper_limit="0.38"/>
                    <measurement group_id="O2" value="-0.14" lower_limit="-0.56" upper_limit="0.27"/>
                    <measurement group_id="O3" value="0.04" lower_limit="-0.38" upper_limit="0.46"/>
                    <measurement group_id="O4" value="0.07" lower_limit="-0.35" upper_limit="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Response</title>
        <description>The SGRQ consists of 76 items in 3 domains: Symptoms (frequency and severity), Activity (activities that cause or are limited by breathlessness) and Impacts (social functioning, psychological disturbances resulting from airways disease). Scores for each domain and a total score are calculated; each questionnaire response has a unique empirically dervied &quot;weight&quot;. Scores range from 0 to 100, with higher scores indicating poor health. Each domain of the questionnaire is scored separately in 2 steps: 1) The weights for all items with a positive response are summed; 2) The score is calculated by dividing the summed weights by the maximum possible weight for that domain and expressing the results as a percentage. The mean SGRQ scores were calculated during the placebo run-in period for baseline and over the last 4 weeks of the 12-week treatment period for on-treatment.</description>
        <time_frame>Baseline and Treatment Weeks 8 and 12</time_frame>
        <population>The modified ITT population includes all participants who had a baseline and at least one posttreatment measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0873 0.75 mg Base Study</title>
            <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 0.75 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)</description>
          </group>
          <group group_id="O2">
            <title>MK-0873 1.25 mg Base Study</title>
            <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 1.25 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)</description>
          </group>
          <group group_id="O3">
            <title>MK-0873 2.5 mg Base Study</title>
            <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 2.5 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)</description>
          </group>
          <group group_id="O4">
            <title>Placebo Base Study</title>
            <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), placebo tablets once daily for 12 weeks in Period II (Base) and placebo tablets once daily for 12 weeks in Period III (EXT1)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Response</title>
          <description>The SGRQ consists of 76 items in 3 domains: Symptoms (frequency and severity), Activity (activities that cause or are limited by breathlessness) and Impacts (social functioning, psychological disturbances resulting from airways disease). Scores for each domain and a total score are calculated; each questionnaire response has a unique empirically dervied &quot;weight&quot;. Scores range from 0 to 100, with higher scores indicating poor health. Each domain of the questionnaire is scored separately in 2 steps: 1) The weights for all items with a positive response are summed; 2) The score is calculated by dividing the summed weights by the maximum possible weight for that domain and expressing the results as a percentage. The mean SGRQ scores were calculated during the placebo run-in period for baseline and over the last 4 weeks of the 12-week treatment period for on-treatment.</description>
          <population>The modified ITT population includes all participants who had a baseline and at least one posttreatment measurement.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="144"/>
                <count group_id="O4" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.92" lower_limit="-4.69" upper_limit="-1.16"/>
                    <measurement group_id="O2" value="-3.26" lower_limit="-5.03" upper_limit="-1.49"/>
                    <measurement group_id="O3" value="-2.08" lower_limit="-3.85" upper_limit="-0.31"/>
                    <measurement group_id="O4" value="-3.22" lower_limit="-4.99" upper_limit="-1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transition Dyspnea Index (TDI) Focal Score</title>
        <description>The baseline dyspnea index (BDI) was measured at the randomization visit as a 3-domain score with a scale of 0 to 4 in each domain, with a total focal score of 12 indicating no dyspnea limitation and 0 indicating severe dyspnea. After 12 weeks of treatment, the investigator-administered TDI was completed, with a change in each of the 3 domains being rated from -3 (major deterioration) to +3 (major improvement), so that the TDI focal score could range from -9 to +9. A higher TDI focal score indicates improvement.</description>
        <time_frame>Baseline and Treatment Week 12</time_frame>
        <population>The modified ITT population includes all participants who had a baseline and at least one posttreatment measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0873 0.75 mg Base Study</title>
            <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 0.75 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)</description>
          </group>
          <group group_id="O2">
            <title>MK-0873 1.25 mg Base Study</title>
            <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 1.25 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)</description>
          </group>
          <group group_id="O3">
            <title>MK-0873 2.5 mg Base Study</title>
            <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 2.5 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)</description>
          </group>
          <group group_id="O4">
            <title>Placebo Base Study</title>
            <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), placebo tablets once daily for 12 weeks in Period II (Base) and placebo tablets once daily for 12 weeks in Period III (EXT1)</description>
          </group>
        </group_list>
        <measure>
          <title>Transition Dyspnea Index (TDI) Focal Score</title>
          <description>The baseline dyspnea index (BDI) was measured at the randomization visit as a 3-domain score with a scale of 0 to 4 in each domain, with a total focal score of 12 indicating no dyspnea limitation and 0 indicating severe dyspnea. After 12 weeks of treatment, the investigator-administered TDI was completed, with a change in each of the 3 domains being rated from -3 (major deterioration) to +3 (major improvement), so that the TDI focal score could range from -9 to +9. A higher TDI focal score indicates improvement.</description>
          <population>The modified ITT population includes all participants who had a baseline and at least one posttreatment measurement.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="3.04" lower_limit="0.95" upper_limit="1.88"/>
                    <measurement group_id="O2" value="1.49" spread="3.07" lower_limit="1.03" upper_limit="1.94"/>
                    <measurement group_id="O3" value="1.41" spread="2.55" lower_limit="0.95" upper_limit="1.87"/>
                    <measurement group_id="O4" value="1.66" spread="2.73" lower_limit="1.20" upper_limit="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Shortness of Breath Questionnaire (SOBQ) Response</title>
        <description>The SOBQ is a validated 24-item measure of dyspnea associated with activities of daily living in patients with moderate to severe chronic lung disease. Twenty-one items ask patients about how frequently they experience shortness of breath (SOB) on a 6-point scale of 0 (never) to 5 (activity given up due to dyspnea) when performing various tasks. Three additional questions about limitations due to SOB, fear of harm from overexertion and fear of SOB are included for a total of 24 items. If patients do not routinely perform the activity indicated in the questionnaire, they are asked to estimate the degree of SOB anticipated. The SOBQ total score is calculated by summing responses across all 24 items. The total score ranges from 0 to 120, with a higher score indicating greater frequency of and limitations due to SOB. The score assessed at the baseline visit was used for the baseline score and the mean score assessed at Treatment Weeks 8 and 12 was used as the on-treatment score.</description>
        <time_frame>Baseline and Treatment Weeks 8 and 12</time_frame>
        <population>The modified ITT population includes all participants who had a baseline and at least one posttreatment measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0873 0.75 mg Base Study</title>
            <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 0.75 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)</description>
          </group>
          <group group_id="O2">
            <title>MK-0873 1.25 mg Base Study</title>
            <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 1.25 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)</description>
          </group>
          <group group_id="O3">
            <title>MK-0873 2.5 mg Base Study</title>
            <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 2.5 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)</description>
          </group>
          <group group_id="O4">
            <title>Placebo Base Study</title>
            <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), placebo tablets once daily for 12 weeks in Period II (Base) and placebo tablets once daily for 12 weeks in Period III (EXT1)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Shortness of Breath Questionnaire (SOBQ) Response</title>
          <description>The SOBQ is a validated 24-item measure of dyspnea associated with activities of daily living in patients with moderate to severe chronic lung disease. Twenty-one items ask patients about how frequently they experience shortness of breath (SOB) on a 6-point scale of 0 (never) to 5 (activity given up due to dyspnea) when performing various tasks. Three additional questions about limitations due to SOB, fear of harm from overexertion and fear of SOB are included for a total of 24 items. If patients do not routinely perform the activity indicated in the questionnaire, they are asked to estimate the degree of SOB anticipated. The SOBQ total score is calculated by summing responses across all 24 items. The total score ranges from 0 to 120, with a higher score indicating greater frequency of and limitations due to SOB. The score assessed at the baseline visit was used for the baseline score and the mean score assessed at Treatment Weeks 8 and 12 was used as the on-treatment score.</description>
          <population>The modified ITT population includes all participants who had a baseline and at least one posttreatment measurement.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="144"/>
                <count group_id="O4" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.90" lower_limit="-5.06" upper_limit="-0.74"/>
                    <measurement group_id="O2" value="-3.12" lower_limit="-5.29" upper_limit="-0.96"/>
                    <measurement group_id="O3" value="-2.28" lower_limit="-4.44" upper_limit="-0.12"/>
                    <measurement group_id="O4" value="-1.08" lower_limit="-3.24" upper_limit="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With at Least One Chronic Obstructive Pulmonary Disease (COPD) Exacerbation</title>
        <description>COPD exacerbation is defined as any change in symptoms or functional status that leads to administration (at investigator's discretion) of systemic corticosteroids (above participant's usual dose) and/or antibiotics, or an unscheduled COPD-related hospitalization, emergency room visit, or doctor visit. The number of participants who experienced at least one COPD exacerbation during the 12-week treatment period is reported.</description>
        <time_frame>Baseline through Treatment Week 12</time_frame>
        <population>The modified ITT population includes all participants who had a baseline and at least one posttreatment measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0873 0.75 mg Base Study</title>
            <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 0.75 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)</description>
          </group>
          <group group_id="O2">
            <title>MK-0873 1.25 mg Base Study</title>
            <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 1.25 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)</description>
          </group>
          <group group_id="O3">
            <title>MK-0873 2.5 mg Base Study</title>
            <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 2.5 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)</description>
          </group>
          <group group_id="O4">
            <title>Placebo Base Study</title>
            <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), placebo tablets once daily for 12 weeks in Period II (Base) and placebo tablets once daily for 12 weeks in Period III (EXT1)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least One Chronic Obstructive Pulmonary Disease (COPD) Exacerbation</title>
          <description>COPD exacerbation is defined as any change in symptoms or functional status that leads to administration (at investigator's discretion) of systemic corticosteroids (above participant's usual dose) and/or antibiotics, or an unscheduled COPD-related hospitalization, emergency room visit, or doctor visit. The number of participants who experienced at least one COPD exacerbation during the 12-week treatment period is reported.</description>
          <population>The modified ITT population includes all participants who had a baseline and at least one posttreatment measurement.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="153"/>
                <count group_id="O4" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Predose (Trough) Forced Vital Capacity (FVC)</title>
        <description>FVC is a measure, in liters and using a spirometer, of the amount of air forcibly exhaled from the lungs after taking the deepest breath possible. The values averaged during the placebo run-in period were used for the baseline measurement and the values averaged over Treatment Weeks 8, 10 and 12 were used for the on-treatment measurement. A higher value indicates greater lung exiratory function.</description>
        <time_frame>Predose at Baseline and Treatment Weeks 8, 10 and 12</time_frame>
        <population>The modified ITT population includes all participants who had a baseline and at least one posttreatment measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0873 0.75 mg Base Study</title>
            <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 0.75 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)</description>
          </group>
          <group group_id="O2">
            <title>MK-0873 1.25 mg Base Study</title>
            <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 1.25 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)</description>
          </group>
          <group group_id="O3">
            <title>MK-0873 2.5 mg Base Study</title>
            <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 2.5 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)</description>
          </group>
          <group group_id="O4">
            <title>Placebo Base Study</title>
            <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), placebo tablets once daily for 12 weeks in Period II (Base) and placebo tablets once daily for 12 weeks in Period III (EXT1)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Predose (Trough) Forced Vital Capacity (FVC)</title>
          <description>FVC is a measure, in liters and using a spirometer, of the amount of air forcibly exhaled from the lungs after taking the deepest breath possible. The values averaged during the placebo run-in period were used for the baseline measurement and the values averaged over Treatment Weeks 8, 10 and 12 were used for the on-treatment measurement. A higher value indicates greater lung exiratory function.</description>
          <population>The modified ITT population includes all participants who had a baseline and at least one posttreatment measurement.</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="153"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.008" lower_limit="-0.053" upper_limit="0.069"/>
                    <measurement group_id="O2" value="-0.082" lower_limit="-0.144" upper_limit="-0.021"/>
                    <measurement group_id="O3" value="-0.002" lower_limit="-0.062" upper_limit="0.058"/>
                    <measurement group_id="O4" value="-0.069" lower_limit="-0.129" upper_limit="-0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 14 weeks in the Base Study; up to 14 weeks in study EXT1; up to 80 weeks in study EXT2</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MK-0873 0.75 mg Base Study</title>
          <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), and MK-0873 0.75 mg tablets once daily for 12 weeks in Period II (Base)</description>
        </group>
        <group group_id="E2">
          <title>MK-0873 1.25 mg Base Study</title>
          <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), and MK-0873 1.25 mg tablets once daily for 12 weeks in Period II (Base)</description>
        </group>
        <group group_id="E3">
          <title>MK-0873 2.5 mg Base Study</title>
          <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 2.5 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)</description>
        </group>
        <group group_id="E4">
          <title>Placebo Base Study</title>
          <description>Participants receive placebo tablets once daily for 3 weeks in Period I (Base), placebo tablets once daily for 12 weeks in Period II (Base) and placebo tablets once daily for 12 weeks in Period III (EXT1)</description>
        </group>
        <group group_id="E5">
          <title>MK-0873 2.5 mg EXT 1</title>
          <description>Participants receive MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)</description>
        </group>
        <group group_id="E6">
          <title>Placebo EXT 1</title>
          <description>Participants receive placebo tablets once daily for 12 weeks in Period III (EXT1)</description>
        </group>
        <group group_id="E7">
          <title>MK-0873 2.5 mg + Usual Care EXT 2</title>
          <description>Participants receive MK-0873 2.5 mg tablets once daily plus usual care (inhaled short- or long-acting beta-agonists, inhaled corticosteroids, or short- or long-acting anticholinergics) for 28 weeks in Periods IV and V (EXT2)</description>
        </group>
        <group group_id="E8">
          <title>Usual Care EXT2</title>
          <description>Participants receive usual care (inhaled short- or long-acting beta-agonists, inhaled corticosteroids, or short- or long-acting anticholinergics) for 28 weeks in Periods IV and V (EXT2)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 8.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="153"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="317"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="187"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="148"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="317"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Colon cancer stage III</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Post-traumatic stress disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="148"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="317"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="187"/>
                <counts group_id="E8" events="4" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 8.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="153"/>
                <counts group_id="E5" subjects_affected="72" subjects_at_risk="317"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="107"/>
                <counts group_id="E7" subjects_affected="37" subjects_at_risk="187"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="150"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="148"/>
                <counts group_id="E3" events="29" subjects_affected="20" subjects_at_risk="153"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E5" events="17" subjects_affected="16" subjects_at_risk="317"/>
                <counts group_id="E6" events="5" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E7" events="9" subjects_affected="8" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="153"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="317"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="150"/>
                <counts group_id="E2" events="21" subjects_affected="14" subjects_at_risk="148"/>
                <counts group_id="E3" events="22" subjects_affected="19" subjects_at_risk="153"/>
                <counts group_id="E4" events="16" subjects_affected="13" subjects_at_risk="153"/>
                <counts group_id="E5" events="22" subjects_affected="18" subjects_at_risk="317"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E7" events="21" subjects_affected="16" subjects_at_risk="187"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="34" subjects_affected="29" subjects_at_risk="150"/>
                <counts group_id="E2" events="30" subjects_affected="26" subjects_at_risk="148"/>
                <counts group_id="E3" events="42" subjects_affected="32" subjects_at_risk="153"/>
                <counts group_id="E4" events="35" subjects_affected="28" subjects_at_risk="153"/>
                <counts group_id="E5" events="52" subjects_affected="40" subjects_at_risk="317"/>
                <counts group_id="E6" events="15" subjects_affected="13" subjects_at_risk="107"/>
                <counts group_id="E7" events="21" subjects_affected="18" subjects_at_risk="187"/>
                <counts group_id="E8" events="8" subjects_affected="7" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The extension studies were terminated based on data from the completed base study suggesting that MK-0873, at doses up to 2.5 mg per day, demonstrated no benefits versus placebo in lung function or symptoms in participants with COPD.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

